Ensysce Biosciences (ENSC) announced it received a Notice of Allowance from the European Patent Office for the issuance of a patent for PF8026, an Attention-Deficit/Hyperactivity Disorder therapy. PF8026 is a novel immediate-release amphetamine prodrug protected by the Company’s proprietary TAAP and MPAR technologies. This newly allowed patent, covering both composition of matter and method of use claims, adds to the Ensysce patent portfolio and secures its subject-matter authority in developing safer treatments for ADHD, a condition affecting millions of children and adults worldwide.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENSC:
- Ensysce’s PF614 Steps Forward in Phase 3 Post-Surgery Pain Trial: What Investors Should Watch
- Ensysce Biosciences CEO says ‘positioned for continued momentum’
- Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614
- Ensysce Biosciences files to sell 4.6M shares of common stock for holders
- Ensysce Biosciences issued notice of allowance for MPAR tech patent